Targeting PML/RARα transcript with DNAzymes results in reduction of proliferation and induction of apoptosis in APL cells

Hematology Journal

Volumn 5, Issue 5, 2004, Pages 426-433

  Kabuli, Majid ^a   Yin, John Ahman Liu ^a   Tobal, Khalid ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

APL; DNAzyme; PML RAR

Indexed keywords

CYTOSINE; DEOXYRIBOZYME; DEOXYRIBOZYME 1; DEOXYRIBOZYME 3; GUANINE; NUCLEOTIDE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; RIBOZYME; RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIPOSOME; MESSENGER RNA; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; RETINOIC ACID; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME SYNTHESIS; FUSION GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; BASE PAIRING; CELL DIVISION; CELL FREE SYSTEM; CELL STRAIN K 562; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENZYME SPECIFICITY; GENETICS; HYDROLYSIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE PAIRING; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CELL-FREE SYSTEM; DNA, CATALYTIC; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE TARGETING; HUMANS; HYDROLYSIS; K562 CELLS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIPOSOMES; NEOPLASM PROTEINS; NUCLEIC ACID CONFORMATION; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SUBSTRATE SPECIFICITY; TRANSFECTION; TRETINOIN;

EID: 5444269937     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200535     Document Type: Article

References (22)

1. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215.
2. Flenghi L, Fagioli M, Tomassoni L, Pilri S, Gambacorta M, Pacini R et al. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. Blood 1995; 85: 1871-1880.
3. James HA, Gibson I. The therapeutic potential of ribozymes. Blood 1998; 91: 371-382.
4. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94: 4262-4266.
5. Santoro SW, Joyce GF. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 1998; 37: 13330-13342.
6. Matsushita H, Kizaki M, Kobayashi H, Ueno H, Muto A, Takayama N et al. Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukaemia cells. Blood 1998; 91: 2452-2458.
7. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 1997; 89: 2259-2267.
8. Unwalla H, Banerjea AC. Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/REV RNA. Biochemical J 2001; 357: 147-155.
9. Beck J, Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acid Res 1995; 23: 4954-4962.
10. Khachigian LM, Fahmy RG, Zhang G, Bobryshev YV, Kaniaros A. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-jun. J Biol Chem 2002; 277: 22985-22991.
11. Cieslak M, Niewiarowska J, Nawrot M, Koziolkiewicz M, Stec WJ, Cierniewski CS. DNAzymes to Beta 1 and Beta 3 mRNA down-regulate expression of the targeted integrins and inhibit enclothelial cell capillary tube formation in fibrin and matrigel. J Biol Chem 2002; 277: 6779-6787.
12. Matsushita H, Kobayashi H, Mori S, Kizaki M, Ikeda Y. Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21). Biochem Biophys Res Commun 1995; 215: 431-437.
13. Snyder DS, Wu Y, McMahon R, Yu L, Rossi JJ, Forman SJ. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Biol Blood Marrow Transplant 1997; 3: 179-186.
14. Nason-Burchenal K, Talke G, Pace U, Flynn S, Allopenna J, Martin P et al. Targeting the PML/RARα translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene 1998; 17: 1759-1768.
15. Wu Y, Yu L, McMahon R, Rossi JJ, Forman SJ, Snyder DS. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (dnazymes). Hum Gene Ther 1999; 10: 2847-2857.
16. Liu C, Cheng R, Sun LQ, Tien P. Suppression of platelet-type 12-lipoxygenase activity in human erythroleukemia cells by an RNA-cleaving DNAzyme. Biochem Biophys Res Commun 2001; 284: 1077-1082.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
18. Dermime S, Grignani F, Clerici M, Nervi C, Sozzi G, Talamo GP et al. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the PML/RARα protein. Blood 1993; 82: 1573-1577.
19. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A et al. Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukaemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241-3249.
20. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JE, Ogden A et al. All-trans-retinoic Acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
21. Zhou DC, Kim SH, Ding W, Schultz C, Warrell Jr RP, Gallagher RE. Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of promyelocytic leukaemia: analysis for functional relationship to response to all-trans-retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002; 99: 1356-1363.
22. Nason-Burchenal K, Allopenna J, Begue A, Stehelin D, Dmitrovsky E, Martin P. Targeting of PML/RARα is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood 1998; 92: 1758-1767.